0
Clinical Investigations: COPD |

Reversal of COPD-Associated Weight Loss Using the Anabolic Agent Oxandrolone*

Shing-shing Yeh, MD; Bernadette DeGuzman, BA; Ted Kramer, MD; for the M012 Study Group
Author and Funding Information

*From the Veterans’ Affairs Medical Center (Dr. Yeh), Northport, NY; and Bio-Technology General Corporation (Ms. DeGuzman and Dr. Kramer), Iselin, NJ.

Correspondence to: Ted Kramer, MD, Director, Medical Affairs, Bio-Technology General Corporation, 70 Wood Ave South, Iselin, NJ 08830; e-mail: tkramer@btgc.com


*From the Veterans’ Affairs Medical Center (Dr. Yeh), Northport, NY; and Bio-Technology General Corporation (Ms. DeGuzman and Dr. Kramer), Iselin, NJ.


Chest. 2002;122(2):421-428. doi:10.1378/chest.122.2.421
Text Size: A A A
Published online

Study objective: Weight loss is a common complication of COPD, associated with negative outcomes. Weight restoration has been associated with improved outcomes. The effects of oxandrolone, an adjunct to help restore weight, were evaluated in patients with COPD.

Design: Prospective, open-label, 4-month clinical trial.

Setting: Twenty-five community-based pulmonary practices throughout the United States.

Patients: A primary pulmonary diagnosis of moderate-to-severe COPD as defined by FEV1 < 50% of predicted and FEV1/FVC ratio < 0.7, along with significant involuntary weight loss (weight ≤ 90% ideal body weight).

Interventions: Oral oxandrolone, 10 mg bid.

Measurements and results: Body weight, body composition (bioelectric impedance analysis), spirometry, and 6-min walking distance were measured. Data for 82 patients at 2 months and 55 patients at 4 months are presented. At month 2, 88% of patients had gained a mean ± SD of 6.0 ± 4.36 lb (p < 0.05) and 12% had lost a mean of 1.7 ± 2.15 lb (not statistically significant [NS]). At month 4, 84% had gained a mean of 6.0 ± 5.83 lb (p < 0.05) and 16% had lost a mean of 1.8 ± 1.74 lb (NS). Month 4 bioelectric impedance analysis showed the weight to be primarily lean tissue, with a mean increase in body cell mass of 3 ± 2.6 lb (p < 0.05), and a mean increase in fat of 1.2 ± 4.6 lb (NS).

Conclusions: Oxandrolone is an effective adjunct to facilitate weight restoration in patients with COPD-associated weight loss. Weight gain is primarily lean body mass. Oxandrolone was relatively well tolerated and, therefore, should be a consideration in the comprehensive management of patients with COPD and weight loss.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543